Effects of recombinant human thyroid stimulating hormone on 131I therapy for the treatment of differentiated thyroid cancer

Guo,Yiling; Zhang,Yingnan; Chen,Zuowei; Xin,Zhenfu

doi:10.3892/etm.2015.2330

Effects of recombinant human thyroid stimulating hormone on 131I therapy for the treatment of differentiated thyroid cancer

Authors:
- Yiling Guo
- Yingnan Zhang
- Zuowei Chen
- Zhenfu Xin
View Affiliations

Affiliations: Department of Nuclear Medicine, People's Hospital of Shenzhen, Shenzhen, Guangdong 518020, P.R. China
Published online on: March 3, 2015 https://doi.org/10.3892/etm.2015.2330
Pages: 1847-1850

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to compare the advantages and disadvantages of the combined application of recombinant human thyroid stimulating hormone (rhTSH) with thyroid hormone withdrawal (THW) and THW alone prior to 131I therapy for the treatment of differentiated thyroid cancer. Four indicators were compared between the experimental group, who received a combined therapeutic method of rhTSH with THW, and the control group, who received THW therapy alone. With the exception of the elimination half‑time of 131I in the blood in the experimental group, which was significantly shorter compared with that in the control group, the other three indicators, including the urinary iodine concentration, the relative 131I uptake ratio of the neck lesions and the one‑time cure rate, were not significantly different between the two groups. In addition, the treatment efficacy of 131I therapy exhibited no statistically significant difference between the experimental and control groups. However, in the experimental group, the residence time of 131I in the blood was significantly shorter compared with that in the control group, indicating that the irradiation damage of radioactive iodine exposure to the non‑target tissues was lower in the experimental group when compared with the control group. In addition, no evident hypothyroidism was observed in the patients. Thus, the combined application of rhTSH with THW prior to 131I therapy was demonstrated to be superior to the THW therapy alone.

View Figures

View References

1	Reiners C, Hӓnscheid H, Luster M, Lassmann M and Verburg FA: Radioiodine for remnant ablation and therapy of metastatic disease. Nat Rev Endocrinol. 7:589–595. 2011. View Article : Google Scholar : PubMed/NCBI
2	Biondi B, Pulcrano M, Pagano L and Lombardi G: Adjuvant treatment with thyrotropin alpha for remnant ablation in thyroid cancer. Biologics. 3:9–13. 2009.PubMed/NCBI
3	Klein HA: Radioiodine dilution due to levothyroxine when using recombinant human thyroid-stimulating hormone: case report and discussion. Clin Nucl Med. 36:899–903. 2011. View Article : Google Scholar : PubMed/NCBI
4	Klubo-Gwiezdzinska J, Burman KD, Van Nostrand D, Mete M, Jonklaas J and Wartofsky L: Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin. Thyroid. 22:310–317. 2012. View Article : Google Scholar : PubMed/NCBI
5	Luster M, Lippi F, Jarzab B, Perros P, Lassmann M, Reiners C and Pacini F: rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocr Relat Cancer. 12:49–64. 2005. View Article : Google Scholar : PubMed/NCBI
6	Tuttle RM, Lopez N, Leboeuf R, et al: Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function. Thyroid. 20:257–263. 2010. View Article : Google Scholar : PubMed/NCBI
7	Cooper DS, Doherty GM, Haugen BR, et al: Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 16:109–142. 2006. View Article : Google Scholar : PubMed/NCBI
8	Pacini F, Schlumberger M, Dralle H, et al: European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 154:787–803. 2006. View Article : Google Scholar : PubMed/NCBI
9	Mazzaferri EL and Kloos RT: Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 86:1447–1463. 2001. View Article : Google Scholar : PubMed/NCBI
10	Schroeder PR, Haugen BR, Pacini F, et al: A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab. 91:878–884. 2006. View Article : Google Scholar : PubMed/NCBI
11	McLeod DS: Current concepts and future directions in differentiated thyroid cancer. Clin Biochem Rev. 31:9–19. 2010.PubMed/NCBI
12	Elisei R, Schlumberger M, Driedger A, et al: Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. J Clin Endocrinol Metab. 94:4171–4179. 2009. View Article : Google Scholar : PubMed/NCBI
13	Phan HT, Jager PL, van der Wal JE, et al: The follow-up of patients with differentiated thyroid cancer and undetectable thyroglobulin (Tg) and Tg antibodies during ablation. Eur J Endocrinol. 158:77–83. 2008. View Article : Google Scholar : PubMed/NCBI
14	de Meer SG, Vriens MR, Zelissen PM, Borel Rinkes IH and de Keizer B: The role of routine diagnostic radioiodine whole-body scintigraphy in patients with high-risk differentiated thyroid cancer. J Nucl Med. 52:56–59. 2011. View Article : Google Scholar : PubMed/NCBI
15	Davies L and Welch HG: Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 295:2164–2167. 2006. View Article : Google Scholar : PubMed/NCBI
16	Enewold L, Zhu K, Ron E, Marrogi AJ, Stojadinovic A, Peoples GE and Devesa SS: Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980–2005. Cancer Epidemiol Biomarkers Prev. 18:784–791. 2009. View Article : Google Scholar : PubMed/NCBI
17	Tuttle RM, Leboeuf R and Martorella AJ: Papillary thyroid cancer: monitoring and therapy. Endocrinol Metab Clin North Am. 36:753–778. 2007. View Article : Google Scholar : PubMed/NCBI
18	Jonklaas J, Sarlis NJ, Litofsky D, et al: Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid. 16:1229–1242. 2006. View Article : Google Scholar : PubMed/NCBI
19	Gosnell JE and Clark OH: Surgical approaches to thyroid tumors. Endocrinol Metab Clin North Am. 37:437–455. 2008. View Article : Google Scholar : PubMed/NCBI
20	Van Nostrand D and Wartofsky L: Radioiodine in the treatment of thyroid cancer. Endocrinol Metab Clin North Am. 36:807–822. 2007. View Article : Google Scholar : PubMed/NCBI
21	Sawka AM, Brierley JD, Tsang RW, et al: An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol Metab Clin North Am. 37:457–480. 2008. View Article : Google Scholar : PubMed/NCBI
22	Brierley J, Tsang R, Panzarella T and Bana N: Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years. Clin Endocrinol (Oxf). 63:418–427. 2005. View Article : Google Scholar : PubMed/NCBI
23	Biondi B, Filetti S and Schlumberger M: Thyroid-hormone therapy and thyroid cancer: a reassessment. Nat Clin Pract Endocrinol Metab. 1:32–40. 2005. View Article : Google Scholar : PubMed/NCBI